Track topics on Twitter Track topics that are important to you
Firstview Insight's Astrocytoma Pricing Market Access and Landscape 2019 provides country specific insights in order to estimate market potential for Astrocytoma based on the pricing and reimbursement scenario and perceived value drivers in different market archetypes. It gives a detailed picture of the disease landscape and unmet needs of different stakeholders existing in the current treatment paradigmThus it enables to identify and leverage on the commercial opportunities spanning across different lines of therapy. The report incorporates detailed analysis of the market development drivers as well as the preventing factors. The scope of the report covers an extensive estimation pertaining to the winning essentials and participant schemes through a presentation of the segmentation of market in the Pricing Market Access landscape.
Astrocytoma is a type of cancer that can form in the brain or spinal cord. Astrocytoma begins in cells called astrocytes that support nerve cells. Astrocytoma signs and symptoms depend on the location oftumor. Astrocytomas that occur in the brain can cause seizures, headaches and nausea. Astrocytomas that occur in the spinal cord can cause weakness and disability in the area affected by the growing tumor.Astrocytoma can be a slowgrowing tumor, or it can be an aggressive cancer that grows quickly. The aggressiveness grade of astrocytoma determines prognosis and treatment options.
Scope of the Report:
Market Access strategy for different payer archetypes
Segmentation and mapping of payers to different archetypes based on their specific criteria of assessment i.e. costeffectiveness, budget impact, clinical effectiveness. This would enable designing effective market strategy for reimbursement in these markets. It also covers the reimbursement decisions and benefit ratings of competitor drugs by different health technology assessment bodies in EU5,US and Japan.
Payer Policy changes and implications
Provides an overview of the changing payer preferences, concerns and evolving requirements. Informs about the payer policies impacting the prescription and uptake of particular product. Estimates the future payer environment and drivers of change.
Innovative pricing and funding mechanisms
With increasing pressure from payers and limitations in evidence development, many innovative payment mechanisms are being introduced such as outcome based reimbursement, annuity based funding etc. This section provides examples of such innovative models and feasibility of their application in a particular disease scenario.
This report contains comprehensive overview of disease including disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends, as well as details about treatment algorithms and treatment guidelines
This section encompasses information on the incidence and prevalence of disease in EU5, US Japan.
Existing and upcoming treatment landscape
Captures the evolution of treatment paradigm including the current and emerging drug therapies. Provides information on the clinical trial results, mechanism of action, route of administration, therapeutic positioning and regulatory milestones. It gives insight into the potential therapeutic targets for drug development.
Market Trends Unmet needs
This section of the report helps to understand the market trend and opportunities by analysing the impact of current therapies on the market, current and future unmet needs, drivers and barriers and demand of better technology. This is determined by analysing the impact of various factors such as mechanism of action, route, cost of therapy, patient segmentation, existing available treatments, compliance and need of the market, expected launch timelines, competitors, brand value and KOLs perception.
Major highlights of the report
Detailed analysis of existing and upcoming competitive landscape
HTA decisions and benefit ratings for :
HASASMR and SMRFrance
Market archetyping and product positioning
Case studies on innovative funding models
Unmet need, major barriers and drivers across the industry:
Value story for achieving reimbursement and premium pricing in different marketsNEXT ARTICLE
According to the American Brain Tumor Association, just over 24,000 patients will be diagnosed with a primary malignant brain tumour during 2012 in the US alone. Some 80% of primary malignant brain tumours are gliomas, a broad term which includes all tum...